Pharmacokinetic drug interactions between anticancer therapeutics and drugs of complementary medicine: Mechanisms and clinical relevance;Pharmakokinetische arzneimittelinteraktionen zwischen tumortherapeutika und arzneimitteln der komplementären medizin: Mechanismen und klinische relevanz

Forschende Komplementarmedizin

Volumn 18, Issue 4, 2011, Pages 213-218

  Unger, Matthias ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Complementary medicine; Cytochrome P450 enzymes; Drug interactions; Herbal drugs; P glycoprotein; St. John's wort; Tumor therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; GLYCOPROTEIN P; PLANT MEDICINAL PRODUCT;

ALTERNATIVE MEDICINE; DRUG EFFECT; DRUG INTERACTION; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEOPLASM; PHARMACOKINETICS; PHYTOTHERAPY; REVIEW;

ANTINEOPLASTIC AGENTS; COMPLEMENTARY THERAPIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; PHARMACOKINETICS; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 80053146261     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000330937     Document Type: Review

References (27)

1. Winking M, Sarikaya S, Rahmanian A, Jödicke A, Böker DK: Boswellic acids inhibit glioma growth: a new treatment option. J Neurooncol 2000;46:97-103. (Pubitemid 30352616)
2. Kirste S, Treier M, Wehrle SJ, Becker G, Abdel-Tawab M, Gerbeth K, Hug MJ, Lubrich B, Grosu AL, Momm F: Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: A prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer 2011; doi: 10.1002/cncr.25945.
3. Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig HH: Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res 2005;25:1969-1975. (Pubitemid 40904592)
4. Eisenbraun J, Scheer R, Kröz M, Schad F, Huber R: Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistle toe extract. Phytomedicine 2011;18:151-157.
5. Nowack R, Andrassy J, Fischereder M, Unger M: Effects of dietary factors on drug transport and metabolism: the impact on dosage guidelines in transplant patients. Clin Pharmacol Ther 2009;85:439-443.
6. Unger M: Pharmakokinetische Arzneimittelinteraktionen durch pflanzliche Arzneimittel - Kritische Bewertung und Klinische Relevanz. Wien Med Wochenschr 2010;160:571-577.
7. Schulz V: Arzneimittelinteraktionen: Relevanz für Phytopharmaka. Z Phytotherapie 2004;25:283-288.
8. Benet LZ: The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 2009;6:1631-1643.
9. Guengerich FP: Cytochromes P450, drugs, and diseases. Mol Interv 2003;3:194-204.
10. Galetin A, Burt H, Gibbons L, Houston JB: Prediction of time-dependent CYP3A4 drug-drug inter actions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34:166-175. (Pubitemid 43042658)
11. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ: The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochem Biophys Acta 2003;619:243-253. (Pubitemid 36163419)
12. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG: Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab Rev 2007;39:699-721.
13. Sharom FJ: Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 2006;84:979-992. (Pubitemid 46450697)
14. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melames MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cyto chem 1990;38:1277-1287. (Pubitemid 20266126)
15. Linnet K, Ejsing TB: A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuro psychopharmacol 2008;18:157-169.
16. Henderson L, Yue OY, Bergquist C, Gerden B, Arlett P: St. John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-356. (Pubitemid 35334946)
17. Martin-Facklam M, Rieger K, Riedel KD, Burhenne J, Walter-Sack I, Haefeli WE: Undeclared exposure to St. John's Wort in hospitalized patients. Br J Clin Pharmacol 2004;58:437-441. (Pubitemid 39312469)
18. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A: Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-1249. (Pubitemid 34993875)
19. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ: Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-329. (Pubitemid 39313122)
20. He SM, Yang AK, Li XT, Du YM, Zhou SF: Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol 2010;6:1195-1213.
21. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke von Zepelin HH, Friede M, Roots I: No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract. Planta Med 2005;71:331-337. (Pubitemid 40676457)
22. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF: Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32:587-594. (Pubitemid 38668150)
23. Van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelder blom H: Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005;11:7800-7806. (Pubitemid 41611624)
24. Xin HW, Wu XC, Li Q, Yu AR, Xiong L: Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers. Br J Clin Pharmacol 2009;67:541-546.
25. Xin HW, Wu XC, Li Q, Yu AR, Zhu M, Shen Y, Su D, Xiong L: Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol 2007;64:469-475. (Pubitemid 47404309)
26. Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y: Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 2008;83:61-69.
27. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK: Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008;52:755-763.